Accessibility Menu
Exicure logo

Exicure(NASDAQ) XCUR

Current Price$1.71
Market Cap$11.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-99%
1 Year-78%
1 Month-36%
Exicure last closing stock price
MetricPriceDate
Last closeUSD 1.762026-07-22
Exicure stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.64%USD 1.622026-07-15
1 month-35.77%USD 2.742026-06-22
3 month-51.65%USD 3.642026-04-23
Year to date-67.53%USD 5.422025-12-31
1 year-77.86%USD 7.952025-07-22
3 year-67.41%USD 5.402023-07-21
5 year-99.18%USD 214.502021-07-23
Since inception-99.62%USD 465.002018-05-22

Exicure Financials at a Glance

Market Cap

$11.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.78M

EPS (TTM)

-$1.54

P/E Ratio

-1.14

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$1.71

Volume

0

Open

$1.87

Previous Close

$1.71

Daily Range

$1.71 - $1.87

52-Week Range

$1.43 - $9.48

Estimated Earnings Date

May 26, 2026

XCUR News

Foolcom-Featured.png

Exicure Posts Wider Loss in Fiscal Q2

Motley Fool Markets TeamAug 8, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Exicure

Exicure develops therapies for neurological pain and hair loss. Its technology aims to help patients with chronic pain or hair disorders. The company now focuses on acquiring and managing clinical-stage assets.

What’s in the Exicure Toolbox?

  • SNA Technology Platform: Developed therapies using spherical nucleic acids for gene regulation (0% of 2025 revenue).
  • SCN9A Program: Preclinical candidate for chronic and neuropathic pain (0% of 2025 revenue).
  • GPCR USA Assets: Clinical-stage oncology program for blood cancer and stem cell mobilization (0% of 2025 revenue).
  • Licensing Agreements: Past collaborations with AbbVie, Ipsen, and Bluejay for hair loss, neurological, and hepatitis therapies (0% of 2025 revenue).
  • Strategic Transactions: Focus on acquisitions, partnerships, and holding acquired assets (100% of current activity).

Growth and Expansion: The Plot Twists

  • Acquired GPCR Therapeutics USA in 2025, adding clinical-stage oncology assets.
  • Sold historical SNA technology and biotech assets to Flashpoint Therapeutics in 2024.
  • Formed and sold South Korean subsidiary KC Creation in 2025 as part of diversification.
  • Entered equity financings with HiTron, SangSang, MIRTO, Shin Chang Partners, and RMS0718 in 2024-2025.
  • Shifted from R&D to a holding company model, seeking new business combinations since 2022.

What Makes Exicure Stand Out?

Exicure now operates as a public holding company, seeking value through acquisitions and partnerships. Its board and investors have strong ties in Asia, supporting cross-border deals. The company leverages its public status for potential mergers and asset management.

Five Things You Need to Know

  • Revenue was $0 in 2025 and $500,000 in 2024.
  • Net loss was $4.95 million in 2025, improving 49% from 2024.
  • Cash and equivalents were $3.7 million as of December 31, 2025.
  • General and administrative expenses rose 25% to $6.83 million in 2025.
  • Accumulated deficit reached $223 million by December 31, 2025.

Bottom Line

Exicure has shifted from drug development to a holding company model. Its future depends on successful acquisitions and strategic transactions.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Jungsoo Kim

Website

www.exicuretx.com

Headquarters

Redwood City, CA 60614, US

XCUR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-179.41%

Return on Capital

-246.64%

Return on Assets

-76.71%

Earnings Yield

-87.72%

Dividend Yield

0.00%

Payout Ratio

-0.81%

Stock Overview

Market Cap

$11.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.37M

Volume

0

Avg. Volume

400.77K

Financials (TTM)

Gross Profit

-$263.00K

Operating Income

-$8.76M

EBITDA

-$9.78M

Operating Cash Flow

-$8.10M

Capital Expenditure

-$1.00K

Free Cash Flow

-$8.10M

Cash & ST Invst.

$2.60M

Total Debt

$22.00K

Exicure Performance Analysis

Exicure annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 28,826,000N/A
20232023-12-31USD 0N/A
20242024-12-31USD 500,000N/A
20252025-12-31USD 0N/A
Exicure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Exicure annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.79-97.4%
20232023-12-31USD -10.55277.6%
20242024-12-31USD -4.75-55.0%
20252025-12-31USD -0.79-83.5%
Exicure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-183.7%
Q32025-09-304.9%
Q42025-12-31-15.4%
Q12026-03-3135.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$106.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$11.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.61M

N/A

Employees

2

N/A

Net Income

-$1.83M

-160.7%

EBITDA

-$1.72M

+41.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.60M

-75.0%

Total Debt

$22.00K

-96.4%

Accounts Receivable

$60.00K

-65.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$22.00K

-96.3%

Return on Assets

-76.71%

N/A

Return on Invested Capital

-1.06%

N/A

Free Cash Flow

-$1.14M

+28.5%

Operating Cash Flow

-$1.14M

+28.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TAOXTAO Synergies Inc.
$3.67+0.27%
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
CVKDCadrenal Therapeutics, Inc. Common Stock
$2.10-3.23%
NRSNNeuroSense Therapeutics Ltd.
$0.65-7.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About XCUR

What is the current price of Exicure?

Exicure is trading at $1.71 per share.

What is the 52-week range for Exicure?

Over the past 52 weeks, Exicure has traded between $1.43 and $9.48.

How much debt does Exicure have?

As of the most recent reporting period, Exicure reported total debt of $22.00K.

How much cash does Exicure have on hand?

Exicure reported $2.60M in cash and cash equivalents in its most recent financial results.

What is Exicure’s dividend yield?

Exicure does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services